Crescent Biopharma

The APOLLO trial assesses CR-002, an investigational antibody-drug conjugate, for safety, tolerability, and preliminary effectiveness in adults with advanced solid tumors.

The ASCEND clinical trial evaluates the safety, tolerability, and preliminary effectiveness of CR-001, an investigational PD-1 and VEGF-targeting bispecific antibody, in adults with advanced cancer.

Clinical trials evaluate investigational medicines for safety and efficacy before approval by agencies like the U.S. Food and Drug Administration.

Crescent focuses on developing therapies to improve outcomes for solid tumor cancers, leveraging innovative approaches in oncology.

Amy Reilly joined Crescent in March 2025 as chief communications officer, with nearly 25 years of experience in life science investor relations, product communications, and corporate philanthropy.

Barbara Bispham joined Crescent as general counsel and corporate secretary in January 2025, after serving in the same roles at Sail Biomedicines.

Crescent appointed Joshua Brumm as CEO in March 2025, following roles at Forbion and as president and CEO of Dyne Therapeutics from 2019 to 2024.

Rick Scalzo joined Crescent as CFO in April 2025, bringing over five years of experience at Dyne Therapeutics, most recently as senior vice president of finance and administration.

Crescent develops high-impact cancer medicines by targeting established pathways, combining multiple modalities, and designing therapies to work alone or synergistically.

Crescent Biopharma’s Healthcare Professional Privacy Notice outlines data collection, purposes, and lawful bases for personal and special category data.

Crescent Biopharma’s Privacy Notice applies to website users, investors, vendors, and others providing personal data, detailing data controller roles and contact methods.